Early sorafenib-related adverse events predict therapy response of TACE plus sorafenib: A multicenter clinical study of 606 HCC patients.

Abstract

The purpose of our study was to test the hypothesis that sorafenib-related dermatologic adverse events (AEs) as an early biomarker can predict the long-term outcomes following the combination therapy of transarterial chemoembolization (TACE) plus sorafenib (TACE-S). The intermediate-stage hepatocellular carcinoma patients who received either TACE-S or TACE… (More)
DOI: 10.1002/ijc.30124

Topics

5 Figures and Tables

Cite this paper

@article{Zhao2016EarlySA, title={Early sorafenib-related adverse events predict therapy response of TACE plus sorafenib: A multicenter clinical study of 606 HCC patients.}, author={Yan Zhao and Hailiang Li and Wei Bai and Jueshi Liu and Weifu Lv and Sonia Sahu and Sheng Guan and Xiao Qin and Wenhui Wang and Weixin Ren and Wei Mu and Weidong Guo and Shanzhi Gu and Yilong Ma and Zhanxin Yin and Wengang Guo and Wenjun Wang and Yongji Wang and Rafael Mart{\'i}n Dur{\'a}n and Daiming Fan and Zhuoli Zhang and Guohong Han}, journal={International journal of cancer}, year={2016}, volume={139 4}, pages={928-37} }